Top

Published in:

Open Access 01-12-2024 | Colorectal Cancer | Research

microRNA-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation

Authors: Yuehong Chen, Feng Liu, Xinhua Chen, Wenyi Li, Kejun Li, Hailang Cai, Shunyi Wang, Honglei Wang, Ke Xu, Chenxi Zhang, Shengzhi Ye, Yunhao Shen, Tingyu Mou, Shumin Cai, Jianwei Zhou, Jiang Yu

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Epigenetic alterations contribute greatly to the development and progression of colorectal cancer, and effect of aberrant miR-622 expression is still controversial. This study aimed to discover miR-622 regulation in CRC proliferation.

Methods

miR-622 expression and prognosis were analyzed in clinical CRC samples from Nanfang Hospital. miR-622 regulation on cell cycle and tumor proliferation was discovered, and FOLR2 was screened as functional target of miR-622 using bioinformatics analysis, which was validated via dual luciferase assay and gain-of-function and loss-of-function experiments both in vitro and in vivo.

Results

miR-622 overexpression in CRC indicated unfavorable prognosis and it regulated cell cycle to promote tumor growth both in vitro and in vivo. FOLR2 is a specific, functional target of miR-622, which negatively correlates with signature genes in cell cycle process to promote CRC proliferation.

Conclusions

miR-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation, proposing a novel mechanism and treatment target in CRC epigenetic regulation of miR-622.

Available only for authorised users

Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54. https://doi.org/10.3322/caac.21772.CrossRefPubMed

Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–8. https://doi.org/10.1126/science.1064921.CrossRefPubMed

Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. Elegans developmental timing. Cell. 2001;106(1):23–34. https://doi.org/10.1016/s0092-8674(01)00431-7.CrossRefPubMed

Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409(6818):363–6. https://doi.org/10.1038/35053110.CrossRefPubMed

Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54. https://doi.org/10.1016/0092-8674(93)90529-y.CrossRefPubMed

Jung G, Hernandez-Illan E, Moreira L, Balaguer F, Goel A. Epigenetics of Colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17(2):111–30. https://doi.org/10.1038/s41575-019-0230-y.CrossRefPubMedPubMedCentral

Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22–36. https://doi.org/10.1038/s41568-020-00306-0.CrossRefPubMed

Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in Oncology. Cell. 2019;179(5):1033–55. https://doi.org/10.1016/j.cell.2019.10.017.CrossRefPubMedPubMedCentral

Balaguer F, Moreira L, Lozano JJ, et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res. 2011;17(19):6239–49. https://doi.org/10.1158/1078-0432.CCR-11-1424.CrossRefPubMedPubMedCentral

10.

Xu L, Hou Y, Tu G, et al. Nuclear Drosha enhances cell invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by dysregulated miRNA-622/197 and their targets LAMC2 and CD82 in gastric cancer. Cell Death Dis. 2017;8(3):e2642. https://doi.org/10.1038/cddis.2017.5.CrossRefPubMedPubMedCentral

11.

Calatayud D, Dehlendorff C, Boisen MK, et al. Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res. 2017;5:8. https://doi.org/10.1186/s40364-017-0087-6.CrossRefPubMedPubMedCentral

12.

Liu S, Hu C, Li M, et al. Estrogen receptor beta promotes Lung cancer invasion via increasing CXCR4 expression. Cell Death Dis. 2022;13(1):70. https://doi.org/10.1038/s41419-022-04514-4.CrossRefPubMedPubMedCentral

13.

Liu H, Liu Y, Liu W, Zhang W, Xu J. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015;6:8494. https://doi.org/10.1038/ncomms9494.CrossRefPubMed

14.

Orlandella FM, Mariniello RM, Mirabelli P, et al. miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of Breast cancer cells through targeting NUAK1 kinase. Br J Cancer. 2020;123(3):426–37. https://doi.org/10.1038/s41416-020-0884-9.CrossRefPubMedPubMedCentral

15.

Vigneron N, Vernon M, Meryet-Figuiere M, et al. Predictive relevance of circulating miR-622 in patients with newly diagnosed and recurrent high-Grade Serous Ovarian Carcinoma. Clin Chem. 2020;66(2):352–62. https://doi.org/10.1093/clinchem/hvz013.CrossRefPubMed

16.

Choi YE, Meghani K, Brault ME, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016;14(3):429–39. https://doi.org/10.1016/j.celrep.2015.12.046.CrossRefPubMedPubMedCentral

17.

Wang Y, Sun J, Wei X, et al. Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in Colorectal cancer cells. Onco Targets Ther. 2017;10:1091–100. https://doi.org/10.2147/OTT.S125724.CrossRefPubMedPubMedCentral

18.

Ma W, Yu J, Qi X, et al. Radiation-induced microRNA-622 causes radioresistance in Colorectal cancer cells by down-regulating rb. Oncotarget. 2015;6(18):15984–94. https://doi.org/10.18632/oncotarget.3762.CrossRefPubMedPubMedCentral

19.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. https://doi.org/10.1158/1078-0432.CCR-04-0713.CrossRefPubMed

20.

Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human Diabetes. Nat Genet. 2003;34(3):267–73. https://doi.org/10.1038/ng1180.CrossRefPubMed

21.

Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005;102(43):15545-50. https://doi.org/10.1073/pnas.0506580102.

22.

Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006;103(10):3687–92. https://doi.org/10.1073/pnas.0511155103.CrossRefPubMedPubMedCentral

23.

Zhou Y, Shao Y, Hu W, et al. A novel long noncoding RNA SP100-AS1 induces radioresistance of Colorectal cancer via sponging miR-622 and stabilizing ATG3. Cell Death Differ. 2023;30(1):111–24. https://doi.org/10.1038/s41418-022-01049-1.CrossRefPubMed

24.

Nawaz FZ, Kipreos ET. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022;33(3):159–74. https://doi.org/10.1016/j.tem.2021.12.003.CrossRefPubMedPubMedCentral

25.

Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y et al. Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer. Cell. 2022;185(7):1189 – 207 e25. https://doi.org/10.1016/j.cell.2022.02.021.

26.

Sharma A, Seow JJW, Dutertre CA, et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in Hepatocellular Carcinoma. Cell. 2020;183(2):377–94e21. https://doi.org/10.1016/j.cell.2020.08.040.CrossRefPubMed

27.

Roy AG, Robinson JM, Sharma P, et al. Folate receptor Beta as a direct and indirect target for antibody-based Cancer Immunotherapy. Int J Mol Sci. 2021;22(11). https://doi.org/10.3390/ijms22115572.

28.

Xu X, Jiang J, Yao L, Ji B. Silencing the FOLR2 gene inhibits cell proliferation and increases apoptosis in the NCI-H1650 Non-small Cell Lung Cancer Cell line via inhibition of AKT/Mammalian target of Rapamycin (mTOR)/Ribosomal protein S6 kinase 1 (S6K1) signaling. Med Sci Monit. 2018;24:8064–73. https://doi.org/10.12659/MSM.911384.CrossRefPubMedPubMedCentral

29.

Boshnjaku V, Shim KW, Tsurubuchi T, et al. Nuclear localization of folate receptor alpha: a new role as a transcription factor. Sci Rep. 2012;2:980. https://doi.org/10.1038/srep00980.CrossRefPubMedPubMedCentral

30.

Mohanty V, Shah A, Allender E, et al. Folate receptor alpha Upregulates Oct4, Sox2 and Klf4 and Downregulates miR-138 and mir-let-7 in cranial neural crest cells. Stem Cells. 2016;34(11):2721–32. https://doi.org/10.1002/stem.2421.CrossRefPubMed

31.

Monick S, Mohanty V, Khan M, et al. A phenotypic switch of differentiated glial cells to dedifferentiated cells is regulated by folate receptor alpha. Stem Cells. 2019;37(11):1441–54. https://doi.org/10.1002/stem.3067.CrossRefPubMed

32.

Harada H, Fujita T, Miyamoto M, et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell. 1989;58(4):729–39. https://doi.org/10.1016/0092-8674(89)90107-4.CrossRefPubMed

33.

Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ, Xie D. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res. 2007;67(6):2535–43. https://doi.org/10.1158/0008-5472.CAN-06-3530.CrossRefPubMed

34.

Gaedcke J, Grade M, Camps J, et al. The rectal cancer microRNAome–microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 2012;18(18):4919–30. https://doi.org/10.1158/1078-0432.CCR-12-0016.CrossRefPubMedPubMedCentral

35.

Pizzini S, Bisognin A, Mandruzzato S, et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of Metastasis. BMC Genomics. 2013;14:589. https://doi.org/10.1186/1471-2164-14-589.CrossRefPubMedPubMedCentral

36.

Perilli L, Pizzini S, Bisognin A, et al. Human miRNome profiling in Colorectal cancer and liver Metastasis development. Genom Data. 2014;2:184–8. https://doi.org/10.1016/j.gdata.2014.06.017.CrossRefPubMedPubMedCentral

37.

Sarver AL, French AJ, Borralho PM, et al. Human colon Cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 2009;9:401. https://doi.org/10.1186/1471-2407-9-401.CrossRefPubMedPubMedCentral

38.

Zhang JX, Song W, Chen ZH, et al. Prognostic and predictive value of a microRNA signature in stage II colon Cancer: a microRNA expression analysis. Lancet Oncol. 2013;14(13):1295–306. https://doi.org/10.1016/S1470-2045(13)70491-1.CrossRefPubMed

39.

Chen DT, Hernandez JM, Shibata D, et al. Complementary strand microRNAs mediate acquisition of metastatic potential in colonic adenocarcinoma. J Gastrointest Surg. 2012;16(5):905–12. https://doi.org/10.1007/s11605-011-1815-0.CrossRefPubMedPubMedCentral

Title: microRNA-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation
Authors: Yuehong Chen
Feng Liu
Xinhua Chen
Wenyi Li
Kejun Li
Hailang Cai
Shunyi Wang
Honglei Wang
Ke Xu
Chenxi Zhang
Shengzhi Ye
Yunhao Shen
Tingyu Mou
Shumin Cai
Jianwei Zhou
Jiang Yu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11766-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Identification of PANoptosis-related signature reveals immune infiltration characteristics and immunotherapy responses for renal cell carcinoma

Elucidating the role of EPPK1 in lung adenocarcinoma development

Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing

Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review

High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line

Amputation in patients with extremity soft tissue sarcoma: the experience of an East Asian referral center

Keynote webinar | Spotlight on antibody–drug conjugates in cancer